Furthermore, elevated levels of apoB‐containing lipoproteins, including LDL‐C and remnant cholesterol, were identified as risk factors for poor response to the combination treatment in advanced NSCLC. The gene discussed is APOB; the disease is non-small cell lung carcinoma.